Clinical trials: Skull
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Cranial Dura Repair
Study of SyntheCelTM Dura Replacement to Other Dura Replacements
Primary Objective: To demonstrate that the SyntheCelTM Dura Replacement performs similarly to or is substantially equivalent to other dura replacements for the repair of the cranial dura in patients undergoing surgical repair of…
- Trial name
- NCT00859508
- Testing
- SyntheCel, Other FDA cleared dura replacements
- Where
- 8 sites in United States
- Volunteers
- 99 people
- Sponsor
- Synthes USA HQ, Inc.
Palatal Neoplasms, Lip Neoplasm
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Objectives Validate the OncAlert® RAPID Test by demonstrating that NPV > (1 -prevalence). Evaluate the independent and associated contribution of readily available clinical variables including age, race, gender, HPV status…
- Conditions
- Palatal Neoplasms, Lip Neoplasm, Gingival Neoplasms, Leukoplakia, Oral
- Trial name
- NCT03239834
- Testing
- OncAlert
- Where
- 26 sites in United States
- Volunteers
- 893 people
- Sponsor
- Vigilant Biosciences, Inc.
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
Convergence Insufficiency
A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in Children
This study is designed to compare the use of special prism glasses to placebo treatment for children with symptomatic convergence insufficiency.
- Trial name
- NCT00347581
- Testing
- Base-in prism glasses for reading
- Where
- 10 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pennsylvania College of Optometry
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia
- Trial name
- NCT03769467
- Testing
- Tabelecleucel, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Atara Biotherapeutics
Cranial Skull Base Bone Removal
The CUSA Clarity Bone Tip Study
The aim of the Study is to investigate the clinical performance and surgeon preferences of the CUSA Clarity Bone Tip during skull base surgery with removal of bony, and other cranial calcified tissue.
- Trial name
- NCT04300075
- Testing
- CUSABT
- Where
- 6 sites in Germany, Greece and 1 more
- Sponsor
- Integra LifeSciences Corporation
Plagiocephaly, Positional, Plagiocephaly, Nonsynostotic
Effectiveness of Ottobock Helmet Therapy in Infants With Plagiocephaly, Brachycephaly or Combination of Both
The objective of the research is to measure the effectiveness of the Ottobock helmet, an innovative 3D-printed cranial orthosis used to correct infant cranial positional deformation: plagiocephaly, brachycephaly or combination of…
- Conditions
- Plagiocephaly, Positional, Plagiocephaly, Nonsynostotic, Brachycephaly
- Trial name
- NCT05154175
- Testing
- Ottobock helmet
- Where
- 12 sites in France
- Volunteers
- 452 people
- Sponsor
- Otto Bock France SNC
Amblyopia, Ocular Motility Disorders
A New Approach to Vision Therapy Based on Naturalistic 3-D Computer Gaming
The research team will execute two concurrent studies within a common framework. The first will compare iCare to standard of care occlusion therapy (patching) for amblyopia in patients ages 4 to 18 (inclusive).
- Trial name
- ICARE (NCT03066063)
- Testing
- iCare, Amblyopia standard of Care, CI standard of Care
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Barron Associates, Inc.
Progressive Supranuclear Palsy, Multiple System Atrophy
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20 subjects will be treated with placebo and NBMI 300 mg in a cross-over design.
- Trial name
- EMERA006 (NCT04184063)
- Testing
- NBMI
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- EmeraMed
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- SAkuraSun (NCT05199688)
- Testing
- Satralizumab
- Where
- 14 sites in United States, Argentina and 7 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Nystagmus, Congenital, Nystagmus, Acquired
Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus
The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN).
- Conditions
- Nystagmus, Congenital, Nystagmus, Acquired, Multiple Sclerosis
- Trial name
- NCT00799942
- Testing
- Neramexane mesylate
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Merz Pharmaceuticals GmbH
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Neoplasm Metastasis, Brain Neoplasms
Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
The primary purpose of the study is to evaluate if motexafin gadolinium with whole brain radiation therapy followed by a stereotactic radiosurgery boost is a safe and effective treatment.
- Trial name
- NCT00121420
- Testing
- Motexafin gadolinium
- Where
- 12 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- Pharmacyclics LLC.
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.
- Trial name
- NCT02073279
- Testing
- Satralizumab
- Where
- 58 sites in United States, Bulgaria and 13 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Non-Arteritic Anterior Ischemic Optic Neuropathy
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION.
- Trial name
- NCT07453888
- Testing
- Cenegermin, Vehicle
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- Dompé Farmaceutici S.p.A
Acute Demylelinating Optic Neuritis
Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)
To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment
- Trial name
- NCT01757691
- Testing
- Fingolimod 0.5mg/daily
- Where
- 2 sites in United States, Spain
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Trigeminal Neuralgia
802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
The primary objective of the study is to evaluate the efficacy of BIIB074 in treating pain experienced by participants with trigeminal neuralgia (TN).
- Trial name
- SURGE-1 (NCT03070132)
- Testing
- BIIB074
- Sponsor
- Biogen
Leber Hereditary Optic Neuropathy
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients
The purpose of this study is to evaluate the safety and tolerability profile of ascending doses of GS010 in Leber Hereditary Optic Neuropathy (LHON) patients.
- Trial name
- NCT02064569
- Testing
- GS010
- Where
- France
- Volunteers
- 19 people
- Sponsor
- GenSight Biologics
Clinical Need for Craniotomy or Craniectomy, Clinical Need for Cranioplasty
A Multi-center, Early Feasibility Study of Using the Mechanical Tissue Resuscitation™ (MTR®) Therapy System for Removal of Excess Fluid in Subjects Who Have Had a Portion of Their Skull Removed to Expose the Dura/Brain and Require Drainage for Fluid Removal.
A multi-center, early feasibility study of using the Mechanical Tissue Resuscitation™ (MTR®) therapy system for removal of excess fluid in subjects who have had a portion of their skull removed to expose the dura/brain and…
- Trial name
- NCT06201429
- Testing
- Mechanical Tissue Resuscitation™ (MTR®)
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Renovo Concepts, Inc.